At the time of writing, Madrigal Pharmaceuticals Inc [MDGL] stock is trading at $338.91, up 8.59%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The MDGL shares have gain 15.12% over the last week, with a monthly amount glided 17.20%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Madrigal Pharmaceuticals Inc [NASDAQ: MDGL] stock has seen the most recent analyst activity on February 28, 2025, when B. Riley Securities upgraded its rating to a Buy and also boosted its price target to $422 from $236. Previously, H.C. Wainwright reaffirmed its Buy rating on February 27, 2025, and elevated its price target to $405. On June 28, 2024, Cantor Fitzgerald initiated with a Neutral rating. Wolfe Research started tracking the stock assigning a Outperform rating and suggested a price target of $382 on June 11, 2024. BofA Securities initiated its recommendation with a Underperform and recommended $150 as its price target on April 22, 2024. B. Riley Securities upgraded its rating to Neutral for this stock on March 15, 2024, and upped its price target to $270. In a note dated March 06, 2024, Citigroup initiated an Buy rating and provided a target price of $382 on this stock.
For the past year, the stock price of Madrigal Pharmaceuticals Inc fluctuated between $200.63 and $377.46. Currently, Wall Street analysts expect the stock to reach $420 within the next 12 months. Madrigal Pharmaceuticals Inc [NASDAQ: MDGL] shares were valued at $338.91 at the most recent close of the market. An investor can expect a potential return of 23.93% based on the average MDGL price forecast.
Analyzing the MDGL fundamentals
According to Madrigal Pharmaceuticals Inc [NASDAQ:MDGL], the company’s sales were 515.55M for trailing twelve months, which represents an 1353.76% jump. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -0.6%, Pretax Profit Margin comes in at -0.55%, and Net Profit Margin reading is -0.55%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.38 and Total Capital is -0.38. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Madrigal Pharmaceuticals Inc [NASDAQ:MDGL] has a current ratio of 5.11. Also, the Quick Ratio is 4.78, while the Cash Ratio stands at 0.95. Considering the valuation of this stock, the price to sales ratio is 14.60, the price to book ratio is 10.82.
Transactions by insiders
Recent insider trading involved Taub Rebecca, Director, that happened on Jul 18 ’25 when 1000.0 shares were sold. Director, FRIEDMAN PAUL A completed a deal on Jul 18 ’25 to sell 1400.0 shares. Meanwhile, Director PAUL FRIEDMAN bought 1400.0 shares on Jul 18 ’25.
